MediMabBio

Private

South KoreaHealthcare & Life Scienceshttps://medimabbio.com/

Last Round

Series B

Oct 24, 2025

Est. Valuation

$13.64M

Total Funding Raised

$38M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

MediMabBio is a biotechnology company that develops protein therapeutics, including therapeutic antibodies and fusion proteins, for the treatment of cancer and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Application

Keywords

fusion proteinstherapeutic antibodiesimmuno-oncologycytokine-antibody fusiondrug discovery platformprecision immune therapeuticsengineered cytokinesantibody engineeringmonoclonal antibodiesbiologics developmentautoimmune disease treatmentrational drug designTIGIT targetingbiotech licensingAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MediMabBio Comps

Public and private peers based on sector, stage, and business model.

MediMabBio comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

MediMabBio Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Oct 24, 2025
Series A	Feb 1, 2021
Pre Seed	Feb 15, 2019

View all Funding Rounds

Key People

Founding team and executive leadership

Eunok Kang

COO

Executive Team

MediMabBio Investors

Notable investors and investment history

MediMabBio investors
Investor	Rounds
Seoul Investment Partners	Series B
Hyundai Investment Partners	Series B
BNH INVESTMENT	Series A, Pre Seed, Series B
Smilegate Investment	Pre Seed, Series B, Series A
iM Investment Partners	Series B
KB Investment	Series B
Timefolio Asset Management	Series B

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jun 20, 2026
Monthly visitors increased 273% MoM, reaching 7.1K.

View all signals

MediMabBio Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

MediMabBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MediMabBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth Korea

Employee Range10

Year Founded2017

Last FundingOct 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.